Development of a ratiometric fluorescence nanosensor for evaluating precision chemotherapy of osteosarcoma through real-time monitoring of caspase-3 activity.

Yunkai Bao, Xiaodong Li, Xiaotong Li, Zhenzhen Hu, Guifeng Liu, Zhenxin Wang

Abstract read

In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunkai BaoState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China.

Xiaodong LiChina-Japan Union Hospital of Jilin University, Changchun, 130033, P. R. China.

Xiaotong LiState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China.

Zhenzhen HuChina-Japan Union Hospital of Jilin University, Changchun, 130033, P. R. China.

Guifeng LiuChina-Japan Union Hospital of Jilin University, Changchun, 130033, P. R. China. gfliu@jlu.edu.cn.

Zhenxin WangState Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China. wangzx@ciac.ac.cn.

Funding

Department of Science and Technology of Jilin Province No. SKL202302030Department of Science and Technology of Jilin Province,China No. 20220203113SF

6 · The paper itself

Abstract

There is an intensive demand for developing personalized precision chemotherapy of osteosarcoma (OS) because chemotherapy is the first-line strategy for treatment of OS, and the conventional OS chemotherapeutic drugs can lead to severe side effects. In this study, a fluorescence resonance energy transfer (FRET)-based ratiometric fluorescence nanosensor, UCNP@PDA@5-TAMRA-pep, has been developed to detect caspase-3 activity with relatively high sensitivity (with a limit of detection of 0.82 ng mL

Indexed as

Antineoplastic AgentsBone NeoplasmsCaspase 3Fluorescent DyesOsteosarcomaAnimalsCell Line, TumorCisplatinFluorescence Resonance Energy TransferHumansIndolesLimit of DetectionMiceMice, Inbred BALB CMice, NudeNanoparticlesAntineoplastic AgentsCaspase 3CisplatinFluorescent DyesIndolespolydopaminePolymersCaspase-3Chemotherapeutic drug-induced apoptosisOsteosarcomaPersonalized precision chemotherapyRatiometric fluorescence nanosensor

Identifiers

PMID41326866

DOI10.1007/s00604-025-07653-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.